| Pharmaceutical Information |
| Drug Name |
Ibritumomab tiuxetan |
| Drug ID |
BADD_D01118 |
| Description |
Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each. |
| Indications and Usage |
For treatment of non-Hodgkin's lymphoma |
| Marketing Status |
Prescription |
| ATC Code |
V10XX02 |
| DrugBank ID |
DB00078
|
| KEGG ID |
D04489
|
| MeSH ID |
C422802
|
| PubChem ID |
92002593
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
72893-007 |
| Synonyms |
ibritumomab tiuxetan | Zevalin | yttrium-90-ibritumomab tiuxetan | IDEC-Y2B8 | IDEC-Y2B8 IDEC-129 | IDEC-129 |
|
| Chemical Information |
| Molecular Formula |
C24H35N5O11 |
| CAS Registry Number |
206181-63-7 |
| SMILES |
CC(CN(CC(CC1=CC=C(C=C1)NC(=O)NC)N(CC(=O)O)CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
